MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.07.05.735339

Медицинская библиотека · bioRxiv : the preprint server for biology · 2026

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.

Dorbin Daniel, Herrera Juliannie, Davidson Raven, Chandrashekar Naveen Kumar, Scheuber Gabrielle, Jayakrishnan Priyanga, Rajesh Christabelle, Johnson Grayson, Yuan Jason, Sochor Matthew, Langenheim John F, Aldakkak Mohammed, Messerly Charles, Wittmann Jacquelyn, Szabo Aniko, Azam Sayahpour Forough, Atallah Nathan L, Peterson Francis C, Volkman Brian F, Ali Mahmoud, Ke Eugene, Evans Douglas B, Tsai Susan, Lytle Nikki K, Seo Y David, Kurzrock Razelle, Hobbs G Aaron, Kamgar Mandana, McFall Thomas

СтатьяПрепринтПеревод в очереди

Аннотация

Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS-alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms between KRASG12D and KRASG12R, alleles with fundamentally different RAS network dynamics. Daraxonrasib inhibited KRASMUT primarily through steric occlusion of effector binding, while engaging RASWT only modestly (~20%). KRASG12R is marked by its inability to transactivate RASWT, and it was observed that daraxonrasib resistant KRASG12R PDAC cells utilize EGFR/RASWT-GTP signaling as the dominant adaptive route. In contrast, KRASG12D resistance arose through retained KRASG12D-GTP signaling, with a decrease of cyclophilin A (CypA) protein, the binding partner required for daraxonrasib activity. The shift from KRASG12R dependence to the EGFR/RASWT conferred sensitivity to trametinib. We confirmed this clinically: a KRASG12R PDAC patient who progressed after 10 months on daraxonrasib showed intratumoral EGFR/RASWT activation, and rapid 3D-bioprinted patient-derived toroid modeling predicted sensitivity to trametinib-based combination therapy. Given the aggressive disease trajectory and lack of response to the two immediately preceding lines of therapy, sixth-line trametinib-based combination therapy achieved approximately 5 months of disease control. This patient ultimately achieved 40 months of overall survival, far exceeding the 8-12 month median for metastatic PDAC. Collectively, these data establish a framework in which allele-specific RAS network topology dictates the adaptive resistance landscape, enabling rational selection of targeted therapies with meaningful clinical benefit in metastatic PDAC.

Для цитирования: Dorbin Daniel, Herrera Juliannie, Davidson Raven, Chandrashekar Naveen Kumar, Scheuber Gabrielle, Jayakrishnan Priyanga, Rajesh Christabelle, Johnson Grayson, Yuan Jason, Sochor Matthew, Langenheim John F, Aldakkak Mohammed, Messerly Charles, Wittmann Jacquelyn, Szabo Aniko, Azam Sayahpour Forough, Atallah Nathan L, Peterson Francis C, Volkman Brian F, Ali Mahmoud, Ke Eugene, Evans Douglas B, Tsai Susan, Lytle Nikki K, Seo Y David, Kurzrock Razelle, Hobbs G Aaron, Kamgar Mandana, McFall Thomas. Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.. bioRxiv : the preprint server for biology. 2026. DOI: 10.64898/2026.07.05.735339.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.